Future management of hemophilia a with non-biologic hemostatic agents: a call for precision coagulation.
INTRODUCTION The therapeutic landscape of hemophilia A has expanded beyond factor replacement with the emergence of non-biologic pharmacological strategies that modulate endogenous hemostatic pathways. These innovations challenge traditional treatment paradigms and create opportunities for more individualized approache...